Health and Fitness Health and Fitness
Thu, April 28, 2011
[ Thu, Apr 28th 2011 ] - WOPRAI
TEG, Utility Stocks Undervalued

Theragenics to Report First Quarter 2011 Financial Results Thursday, May 5


Published on 2011-04-28 04:16:14 - Market Wire
  Print publication without navigation


BUFORD, Ga.--([ BUSINESS WIRE ])--Theragenics Corporation® (NYSE:TGX) expects to release first quarter 2011 financial results before the market opens on May 5, 2011. Following this release, the Company will host a conference call at 11:00 a.m. Eastern.

To participate in the call, dial 877-407-4019 or 201-689-8337. The call is also being webcast and can be accessed via Theragenicsa™ website, [ www.theragenics.com ]. A replay will be available on the website for one month. A phone replay will be available until Midnight, May 12, 2011 by dialing 877-660-6853 or 201-612-7415, and entering the account # 372 and conference ID 371625.

Theragenics Corporation (NYSE: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. Its surgical products business ([ www.cpmedical.com ], [ www.galtmedical.com ], [ www.needletech.com ]) manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, and other needle based products. The surgical products segment serves a number of markets and applications, including, among others, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenicsa™ brachytherapy business manufactures, markets and distributes aseedsa used primarily in the minimally invasive treatment of localized prostate cancer. The Companya™s brachytherapy product line includes its palladium-103 TheraSeed® device ([ www.theraseed.com ]), and the iodine-125 based devices I-Seed and OncoSeeda".